Qfitlia helps restore hemostasis by lowering antithrombin for people with hemophilia A or B, with or without inhibitors1
Qfitlia offers the fewest doses for any prophylactic treatment1,3-15

As few as 6 injections a year1
- The starting dose of Qfitlia is 50 mg every two months
- Antithrombin activity levels must be measured, and the dose should be adjusted, if needed, to ensure that antithrombin levels between 15% and 35% are achieved
- In the clinical study of 227 patients, ~67% of people with hemophilia took Qfitlia every other month, and ~19% took it monthly
MOA=mechanism of action.
References
-
Qfitlia Prescribing Information. Genzyme Corporation. Cambridge, MA.
-
Machin N, et al. J Blood Med. 2018;9:135-140.
-
Advate Prescribing Information. Takeda Pharmaceuticals U.S.A., Inc. Lexington, MA.
-
Adynovate Prescribing Information. Takeda Pharmaceutical U.S.A., Inc. Lexington, MA.
-
Afstyla Prescribing Information. CSL Behring LLC. Kankakee, IL.
-
ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA.
-
Esperoct Prescribing Information. Novo Nordisk Inc. Plainsboro, NJ.
-
Helixate Prescribing Information. CSL Behring LLC. Kankakee, IL.
-
Hemlibra Prescribing Information. Genentech, Inc. San Francisco, CA.
-
Jivi Prescribing Information. Bayer HealthCare LLC. Whippany, NJ.
-
Kogenate Prescribing Information. Bayer HealthCare LLC. Whippany, NJ.
-
Kovaltry Prescribing Information. Bayer HealthCare LLC. Whippany, NJ.
-
Novoeight Prescribing Information. Novo Nordisk Inc. Plainsboro, NJ.
-
Nuwiq Prescribing Information. Octapharma USA, Inc. Paramus, NJ.
-
Xyntha Prescribing Information. Wyeth Pharmaceuticals LLC. Philadelphia, PA.